RESprotect granted ACU a North American license to RP101, a chemopotentiator that has completed a Phase I/II trial in metastatic breast, ovarian and pancreatic cancers, as well as small cell and non-small cell lung cancers. An expansion of that trial is ongoing in metastatic pancreatic cancer. RESprotect said RP101 down-regulates the oncogene STAT3 and APEX, a DNA repair gene, which are overexpressed in pancreatic cancer. ACU plans to submit an IND in 2005 and will seek Orphan Drug designation for pancreatic cancer.